Role of heparin and low-molecular-weight heparins in the management of acute ischemic stroke

Expert Review of Cardiovascular Therapy

Volumn 4, Issue 3, 2006, Pages 405-415

  Padma, Vasantha ^a   Fisher, Marc ^b   Moonis, Majaz ^b  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Heparin; Ischemic stroke; Low molecular weight heparin; Pulmonary embolism; Stroke; Thromboembolism; Venous stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBIN III; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR 10A; CERTOPARIN; DANAPAROID; ENOXAPARIN; HEPARIN; HEPARIN DERIVATIVE; HEPARINOID; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PLACEBO; THROMBIN; THROMBIN INHIBITOR; TINZAPARIN; UROKINASE;

ANTICOAGULATION; AWARENESS; BLEEDING DISORDER; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CHINESE; CLINICAL STUDY; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG PROTEIN BINDING; ENZYME INHIBITION; EXPERIENCE; HEART INFARCTION; HEMATOMA; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HYPERGLYCEMIA; HYPERTENSION; LUNG EMBOLISM; MEDICAL TECHNOLOGY; META ANALYSIS; METHODOLOGY; NEUROIMAGING; NEUROLOGIC DISEASE; OCCLUSIVE CEREBROVASCULAR DISEASE; OSTEOPOROSIS; PATHOPHYSIOLOGY; PATIENT CARE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; QUALITY CONTROL; RANDOMIZATION; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; STROKE PATIENT; SYSTEMATIC REVIEW; THROMBOEMBOLISM; THROMBOGENESIS; VASCULAR DISEASE; VEIN THROMBOSIS;

ACUTE DISEASE; ANTICOAGULANTS; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INTRACRANIAL THROMBOSIS; RECURRENCE; VENOUS THROMBOSIS;

EID: 33744473766     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.4.3.405     Document Type: Review

References (46)

1. Teal PS, Pessin MS. Hemorrhagic Transformation: the spectrum of ischemiarelated brain hemorrhage. Neurosurg. Clin. N. Am. 3, 601-610 (1992).
2. Cardiogenic brain embolism: the second report of the Cerebral Embolism Task Force. Arch Neurol. 46, 727-743 (1989).
3. Hart RG, Boop BS, Tong DC, Yenari MA, Albers GW. Safety of heparin in acute ischemic stroke. Neurology 46, 589; discussion 589-591 (1996).
4. Hart RG, Easton JD. Hemorrhagic infarcts. Stroke 17, 586-589 (1986).
5. Koller RL. Recurrent embolic cerebral infarction and anticoagulation. Neurology 32, 283-285 (1982).
6. Sacco RL, Foulkes MA, Mohr JP, Wolf PA, Hier DB, Price TR. Determinants of early recurrence of cerebral infarction: the Stroke Data Bank. Stroke 20, 983-989 (1989).
7. Moonis M, Fisher M. Considering the role of heparin and low-molecular weight heparins in acute ischemic stroke. Stroke 33, 1927-1933 (2002).
8. The International Stroke Trial (IST): a randomized trial of aspirin, subcutaneous heparin both or neither among 19435 patients with acute ischemic stroke. International Stroke Trial Collaborative group. Lancet 349, 1569-1581 (1997).
9. Low-molecular-weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial: the Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. JAMA 279, 1265-1272 (1998).
10. Sacco RL, Shi T, Zamanillo MC, Kargiman DE. Predictors of mortality and recurrence after hospitalized cerebral infarction in an urban community: the Northern Manhattan Stroke Study. Neurology 44, 626-634 (1994).
11. Berge E, Abdelnoor M, Nakstad PH, Sandset PM. Low molecular-weight heparin versus aspirin in patients with acute ischemic stroke and atrial fibrillation: a double-blind randomised study: HAEST Study Group Heparin in Acute Embolic Stroke Trial. Lancet 355, 1205-1210 (2000).
12. CAST (Chinese Acute Stroke Trial). Collaborative group. CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischemic stroke. Lancet 349, 1641-1649 (1997).
13. Chen ZM, Sandercock P, Pan HC et al. Indications for early aspirin use in acute ischemic stroke: a combined analysis of 40,000 randomized patients from the Chinese Acute Stroke Trial and the International Stroke Trial. Stroke 31, 1240-1249 (2000).
14. Cardiogenic brain embolism. Cerebral Embolism Task Force. Arch Neurol. 43(1), 71-84 (1986).
15. Johannessen KA. Peripheral emboli from left ventricular thrombi of different echo cardio graphic appearance in acute myocardial infarction. Arch. Infern. Med. 147, 641-644 (1987).
16. Johannessen KA, Nordelaug JE, von der Lippe G. Prophylactic anticoagulation for LV thrombi after AMI. Am. Heart J. 115, 1337-1338 (1988).
17. Johannessen KA, Nordehaug JE, von der Lippe G, Vollset SE. Risk factors for embolization in patients with left ventricular thrombo and acute myocardial infarction. Br. Heart J. 60, 104-110 (1988).
18. Duke RJ, Bloch RF, Turpe AG, Trebilcock R, Bayer N. Intravenous heparin for the prevention of stroke progression in acute partial stable stroke. Ann. Intern. Med. 105(60), 825-828 (1986).
19. Chamorro A, Vila N, Ascaso C, Blane R. Heparin in acute stroke with atrial fibrillation: clinical relevance of very early treatment. Arch Neurol. 56(9), 1098-1102 (1999).
20. Daffertshofer M, Grips E, Dempfle CE, Hennerici M. Heparin during acute ischemic stroke. Present data and clinical situation. Nervenarzt 74(4), 307-319 (2003).
21. Bath PMW, Iddenden R, Bath FJ. Low-molecular-weight heparins and heparinoids in acute ischemic stroke. A meta-analysis of randomized controlled trials. Stroke 31, 1770-1778 (2000).
22. Hommel M; for the FISS his Investigators Group. Fraxiparine in ischemic stroke study (FISS bis). Cerebrovasc, Dis. 19: Abstract (1988).
23. Kay R, Wong KS, Yu YL et al. Low-molecular-weight heparin for the treatment of acute ischemic stroke. N. Engl. J. Med. 333, 1588-1593 (1995).
24. Diener HC, Ringlelstein EB, von Kummer R et al. Treatment of acute ischemic stroke with the low-molecular-weight heparin certoparin; results of the TOPAS trial. Stroke 32, 22-29 (2001).
25. de Bruijn SFTM, Stam J; for the Cerebral Venous Thrombosis Study Group. Randomized, placebo controlled trial of anticoagulant treatment with low-molecular-weight heparin for cerebral sinus thrombosis. Stroke 30, 484-488 (1999).
26. Gubitz G, Consell C, Sandercock P, Signorini D. Anticoagulants for acute ischemic stroke. Cochrane. Database Syst. Rev. (2), CD000024 (2000).
27. Sandercock P, Mielke O, Liu M, Councsell C. Anticoagulants for preventing recurrence following presumed non-cardioemblic ischemic stroke or transient ischemic attack. Cochrane. Database Syst. Rev. (1), CD 000248 (2003).
28. Counsell C, Sandercock P. Low-molecular weight heparins or heparinoids versus standard unfractionated heparin for acute ischemic stroke. Cochrane. Database Syst. Rev. (4), CD 000119 (2001).
29. Berge E, Sandercock P. Anticoagulants versus antiplatelet agents for acute ischemic stroke (Cochrane Review). Cochrane Database Syst. Rev. (2), CD003242 (2001).
30. Lyrer P, Engelter S. Antithrombotic drugs for carotid artery dissection. Cochrane Database Syst. Rev. (1), CD000255 (2003).
31. Caplan L. Resolved: heparin may be useful in selected patients with brain ischemia. Stroke 34, 230-231 (2003).
32. Berge E, Adkelnoor M, Nakstad PH, Sandset PM. Low-molecular-weight heparin versus aspirin in patients with acute ischemic stroke and atrial fibrillation: a double-blind randomized study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. Lancet 355, 1205-1210 (2000).
33. Phan TG, Koh M, Wijdicks EFM. Safety of discontinuation of anticoagulation in patients with intracranial hemorrhage at high thromboembolic risk. Arch Neurol. 57, 1710-1713 (2000).
34. Cerebral Embolism Task Force. Cardiogenic rain emblism. Arch Neurol. 43, 71-84 (1986).
35. Caplan LR. Worsening in ischemic stroke patients: is it time for a new strategy? Stroke. 33, 1443-1445 (2002).
36. Tong DC, Adam A, Moseley ME, Marks MP. Relationship between diffusion coefficient and subsequent hemorrhagic transformation following acute ischemic stroke. Stroke 31, 2378-2384 (2000).
37. Einhaupl KM, Villringer A, Meister W et al. Heparin treatemnt in sinus venous thrombosis. Lancet 338, 597-600 (1991).
38. Meister W, Einhaupl K, Villringer A et al. Treatment of patients with cerebral sinus and vein thrombosis with heparin. In: Cerebral Sinus Thrombosis Experimental and Clinical Aspects. Einhaupl K, Kempski O, Baethmann A (Eds). Plenum, NY, USA, 225-230 (1990).
39. de Bruijn SFTM, Stam J; for the Cerebral Venous Sinus Thrombosis Study Group. Randomized, placebo-controlled trial of anticoagulant treatment with low-molecular weight heparin for cerebral venous sinus thrombosis. Stroke 30, 484-488 (1999).
40. Ameri A, Bousser MG. Cerebral cvenous thrombosis. Neurol. Clin. 10, 87-111 (1992).
41. Jacewicz M, Plum F. Aseptic cerebral venous thrombosis. In: Cerebral Sinus Thrombosis: Experimental and Clinical Aspects. Einhaupl K, Kempski O, Baethmann A (Eds). Plenum; NY, USA. 157-170 (1990).
42. Leizoroviez A, Haugh MC, Chapuis F-R, Samama MM, Boisel J-P. Low-molecular-weight heparin in prevention of perioperative thrombosis. Br. Med. J. 305, 913-920 (1992).
43. Lensing WA, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparins: a meta-analysis. Arch. Intern. Med. 155, 601-607 (1995).
44. Cohen M, Demers C, Gurfinkel EP et al. The efficacy and safety of subcutaneous enoxaparin in non-Q-wave coronary events study group. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N. Engl. J. Med. 337, 447-452 (1997).
45. Mcarthy ST, Turner J. Low dose subcutaneous heparin in the prevention of deep vein thrombosis and pulmonary emboli following acute stroke. Age Aging. 15, 84-88 (1986).
46. Coull BM, Williams LS, Goldstein LB et al. Anticoagulants and antiplatelet agents in acute ischemic stroke. Stroke 33, 1934-1942 (2002).